Type 1 diabetes.
| Autor: | Quattrin T; Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Diabetes Center, John R Oishei Children's Hospital, Buffalo, NY, USA. Electronic address: tquattrin@upa.chob.edu., Mastrandrea LD; Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Diabetes Center, John R Oishei Children's Hospital, Buffalo, NY, USA., Walker LSK; Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Lancet (London, England) [Lancet] 2023 Jun 24; Vol. 401 (10394), pp. 2149-2162. Date of Electronic Publication: 2023 Apr 05. |
| DOI: | 10.1016/S0140-6736(23)00223-4 |
| Abstrakt: | Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic β cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced knowledge related to the pathophysiology of the disease, including interactions between genetic, immune, and environmental contributions, and major strides in treatment and management, disease burden remains high. Studies aimed at blocking the immune attack on β cells in people at risk or individuals with very early onset type 1 diabetes show promise in preserving endogenous insulin production. This Seminar will review the field of type 1 diabetes, highlighting recent progress within the past 5 years, challenges to clinical care, and future directions in research, including strategies to prevent, manage, and cure the disease. Competing Interests: Declaration of interests TQ is a consultant for Jansen Research & Development, Merck, and Provention-Bio; a clinical site principal investigator (Buffalo, NY) for Janssen, Provention Bio, and TrialNet; and a sub-investigator for Novo Nordisk. LDM is a clinical site principal investigator (Buffalo, NY) for Novo Nordisk and JDRF, and a sub-investigator for Provention Bio and TrialNet. LDM is a member of the manuscript writing team for Novo Nordisk. LSKW received funding from the UK's Medical Research Council and Diabetes UK. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|